DeepBiome Therapeutics

DeepBiome Therapeutics was a private U.S. biotechnology company focused on discovering therapeutics from the human microbiome using a platform that combined deep learning, sequencing, and synthetic biology. The company described its core capability as analyzing microbiome genetic data, uncovering therapeutic mechanisms, and designing biological circuits to generate drug candidates, including small molecules and microbiome-derived therapeutics. Public company databases and startup trackers indicate the business was founded in 2017 in the Boston/Cambridge area and remained an early-stage, venture-backed platform company rather than a clinical-stage drug developer. Available public sources do not identify a disclosed clinical pipeline with named human-stage assets. Multiple business databases now list the company as closed or inactive.